MicroDerm

Phase 3Biologic

OOhio State University

MicroDerm is one of 38 biologic programs targeting Age. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AgeActive, not recruiting

AgePhase 3

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Age

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Rapamune

PPrism Pharmaceuticals

Approved

—3

Decadron

AAspen Global Incorporated

Phase 2

3 4

Rezurock

KKadmon, a Sanofi Company

Phase 2

1 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 6

Venclexta

AbbVie

Phase 1

3 7

Acotiamide

GGetz Pharma

Phase 3

1 8

Evorpacept

AALX Oncology Inc.

Phase 2

1 9

APG-2575

Ascentage Pharma Group Inc.

Phase 2

1 10

APG-115

Ascentage Pharma Group Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Age

NCT07203326

Clinical

Trials by Indication[1]

Age1 trial

Microderm for Root Coverage Procedures

Active, not recruiting·OOhio State University·Phase 4·NCT07203326·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MicroDerm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MicroDerm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MicroDerm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ohio State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: OOhio State University

MicroDerm

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Age1 trial

References

Drug Info

Quick Facts

Related News